Ibio Inc's Comment on Sales, Marketing and Customers
The company provides services to licensees, collaborators, and partners engaged in drug candidate development, with a focus on disease areas related to obesity therapeutics. Its market includes next-generation obesity treatments, competing with various companies and therapeutic approaches such as incretin peptides, biologics, peptide therapies, siRNAs, surgical interventions, and small molecules. Competitors include fully integrated pharmaceutical companies, established biotechnology firms, companies specializing in obesity and cardiometabolic conditions, and technology-enabled drug discovery companies. Research and development activities are primarily conducted at the company's facilities in San Diego.
Customers and market participants identified in company filings include Abcellera Biologics, Inc., Aduro Biotech, Inc., Advaxis, Inc., Agenus Inc., Alnylam Pharmaceuticals, Inc., Amgen Inc., Arrowhead Pharmaceuticals, Inc., AstraZeneca plc, Basecure Therapeutics Inc., Bausch Health Companies, Bavarian Nordic A/S, BenevolentAI, Biohaven Ltd., Bluebird Bio, Inc., Bristol-Myers Squibb Company, Cellarity, Inc., Celldex Therapeutics, Inc., Eli Lilly and Company, Genentech, Inc., Gilead Sciences, Inc., Helicore Biopharma Inc., ImmunoCellular Therapeutics, Ltd., IMV Inc., Johnson & Johnson, Keros Therapeutics, Inc., Kite Pharma, Inc., Laekna, Inc., Lumos Pharma, MedImmune, LLC, Merck & Co., Inc., Merck KGaA, Nabla Technologies, Inc., Novartis AG, Novo Nordisk A/S, Oxford BioMedica plc, Pfizer Inc., Planet Biotechnology, Inc., Recursion Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc., Roche Group, Sanofi SA, Scholar Rock Holding Corporation, Scholar Rock, Inc., Skye Bioscience, Inc., Structure Therapeutics, Inc., Terns Pharmaceuticals, Inc., Transgene SA, Veru Inc., Viking Therapeutics, Inc., Wave Life Sciences Ltd., and Zealand Pharma A/S.
The fight against obesity and cardiometabolic diseases continues to present significant challenges for the healthcare industry. However, a beacon of hope arises as two leading innovators, iBio and AstralBio, join forces in a transformative collaboration. Harnessing the power of Artificial Intelligence (AI) and precision biologics, this groundbreaking partnership aims to rapidly develop novel antibodies to combat obesity and related disorders. This article delves into the details of this pioneering collaboration, highlighting its potential to revolutionize treatment options for millions of individuals worldwide.Obesity and Cardiometabolic Diseases: A Growing Global Concern:Obesity and cardiometabolic diseases...
Ibio Inc’s Comment on Sales, Marketing and Customers
The company provides services to licensees, collaborators, and partners engaged in drug candidate development, with a focus on disease areas related to obesity therapeutics. Its market includes next-generation obesity treatments, competing with various companies and therapeutic approaches such as incretin peptides, biologics, peptide therapies, siRNAs, surgical interventions, and small molecules. Competitors include fully integrated pharmaceutical companies, established biotechnology firms, companies specializing in obesity and cardiometabolic conditions, and technology-enabled drug discovery companies. Research and development activities are primarily conducted at the company's facilities in San Diego.
Customers and market participants identified in company filings include Abcellera Biologics, Inc., Aduro Biotech, Inc., Advaxis, Inc., Agenus Inc., Alnylam Pharmaceuticals, Inc., Amgen Inc., Arrowhead Pharmaceuticals, Inc., AstraZeneca plc, Basecure Therapeutics Inc., Bausch Health Companies, Bavarian Nordic A/S, BenevolentAI, Biohaven Ltd., Bluebird Bio, Inc., Bristol-Myers Squibb Company, Cellarity, Inc., Celldex Therapeutics, Inc., Eli Lilly and Company, Genentech, Inc., Gilead Sciences, Inc., Helicore Biopharma Inc., ImmunoCellular Therapeutics, Ltd., IMV Inc., Johnson & Johnson, Keros Therapeutics, Inc., Kite Pharma, Inc., Laekna, Inc., Lumos Pharma, MedImmune, LLC, Merck & Co., Inc., Merck KGaA, Nabla Technologies, Inc., Novartis AG, Novo Nordisk A/S, Oxford BioMedica plc, Pfizer Inc., Planet Biotechnology, Inc., Recursion Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc., Roche Group, Sanofi SA, Scholar Rock Holding Corporation, Scholar Rock, Inc., Skye Bioscience, Inc., Structure Therapeutics, Inc., Terns Pharmaceuticals, Inc., Transgene SA, Veru Inc., Viking Therapeutics, Inc., Wave Life Sciences Ltd., and Zealand Pharma A/S.
Sources:
Ibio inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Ibio inc’s corporate clients.
For your research, we’ve provided 9 tables on Ibio inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
